Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$194k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
17.6% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
20
users have followed this narrative
New
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
1.1% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
17
users have liked this narrative
7
users have commented on this narrative
24
users have followed this narrative
9 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
4.7% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
18
users have liked this narrative
7
users have commented on this narrative
22
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
45.5% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
PTC
AN
AnalystConsensusTarget
Consensus Narrative from 19 Analysts
AI Capabilities And NVIDIA Partnership Will Modernize Manufacturing Processes
Key Takeaways Accelerating AI adoption, SaaS transition, and product integration are driving higher recurring revenues, improved margins, and stronger customer retention. Strategic partnerships and targeted sales efforts are expanding market reach, boosting cross-sell opportunities, and increasing platform criticality for customers.
View narrative
US$224.68
FV
6.1% undervalued
intrinsic discount
9.61%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
12
users have followed this narrative
about 21 hours ago
author updated this narrative
Organon
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
New Product Launches And Biosimilars Will Open Global Healthcare Markets
Key Takeaways New product launches and biosimilars adoption are driving market share growth, while portfolio shifts and operational efficiencies support stronger margins. Expanding presence in global and emerging markets, together with improving financial flexibility, positions the company for sustained revenue growth and strategic investments.
View narrative
US$13.17
FV
28.8% undervalued
intrinsic discount
1.17%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
27
users have followed this narrative
about 21 hours ago
author updated this narrative
KeyCorp
AN
AnalystConsensusTarget
Consensus Narrative from 22 Analysts
Strategic Shifts And Market Expansion Positively Impacting Bank's Profitability And Growth
Key Takeaways Shift from net interest income headwinds to tailwinds and strategic deposit cost management expected to enhance revenue growth and profitability. Expansion in wealth management and commercial payments, alongside strong growth in commercial loan servicing, poised to drive noninterest income and earnings stability.
View narrative
US$21.17
FV
13.9% undervalued
intrinsic discount
19.41%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
16
users have followed this narrative
Updated
narrative
Akeso
AN
AnalystConsensusTarget
Consensus Narrative from 20 Analysts
Cadonilimab And Ivonescimab Trials Will Broaden Market Access
Key Takeaways Akeso's strategic focus on bispecific antibodies and NRDL inclusion could drive significant revenue growth and expand market access. Collaborations and a robust R&D pipeline signal long-term growth and potential market expansion, bolstering future earnings and global positioning.
View narrative
HK$125.08
FV
34.3% overvalued
intrinsic discount
56.76%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
Updated
narrative
Nebius Group
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Overvaluation Will Crumble Under Intensifying Regulatory And Cost Pressures
Key Takeaways Intensifying competition, open-source adoption, and regulatory hurdles threaten Nebius Group's profitability, margin stability, and expansion prospects in key markets. High capital requirements and limited global brand recognition may constrain sustainable earnings, customer diversification, and long-term growth opportunities.
View narrative
US$89.40
FV
24.5% undervalued
intrinsic discount
160.89%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
122
users have followed this narrative
Updated
narrative
Nazara Technologies
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
Regulatory Hurdles And Global Competition Will Test Gaming Expansion
Key Takeaways Heightened competition, regulatory challenges, and reliance on external platforms threaten Nazara's growth prospects and profitability sustainability. Heavy investment in esports and gamified learning is not yielding consistent profitability, with limited progress on global expansion and margin improvement.
View narrative
₹1.25k
FV
3.7% undervalued
intrinsic discount
17.25%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
Updated
narrative
Shield Therapeutics
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Single Asset Dependency And US Pricing Challenges Will Mar Prospects
Key Takeaways Dependence on a single product and increasing generic competition heighten vulnerability to revenue loss and market share erosion. Pricing pressures, restrictive reimbursement, and rising regulatory demands threaten margin sustainability and long-term profitability.
View narrative
UK£0.032
FV
123.4% overvalued
intrinsic discount
49.60%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
DarioHealth
AN
AnalystLowTarget
Consensus Narrative from 4 Analysts
Digital Health Onboarding Delays And Rising Costs Will Ease Eventually
Key Takeaways Persistent onboarding delays and client turnover risk short-term revenue, while macroeconomic uncertainty and enterprise budget constraints may limit new customer growth. Margin gains via AI and analytics are offset by the need for sustained R&D investment and sector challenges that delay profitability and consistent earnings growth.
View narrative
US$0.60
FV
27.9% undervalued
intrinsic discount
9.27%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Wisr
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
Australian Lending Risks Will Strain Margins Yet Allow Recovery
Key Takeaways Increased regulatory scrutiny, dependence on wholesale funding, and cost-of-living pressures could restrict loan growth, compress margins, and heighten default risks. Rising competition from tech players and demographic shifts may erode Wisr's market share, limit pricing power, and cap long-term revenue expansion.
View narrative
AU$0.067
FV
53.0% undervalued
intrinsic discount
112.26%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Value any company in seconds
Popular companies